Dendrimers are structurally well-defined, synthetic polymers with sizes and physicochemical properties often resembling those of biomacromolecules (e.g. proteins). As a result they are promising candidates for peptide-based vaccine delivery platforms. Herein, we established a synthetic pathway to conjugate a human papillomavirus (HPV) E7 protein-derived peptide antigen to a star-polymer to create a macromolecular vaccine candidate to treat HPV-related cancers. These conjugates were able to reduce tumor growth and eradicate E7-expressing TC-1 tumors in mice after a single immunization, without the help of any external adjuvant.
INTRODUCTION
Vaccination is one of the most cost-effective public health interventions, and has been proposed as a promising strategy for the treatment of cancer. 1 Cervical cancer results from the infection of the cervix with human papillomavirus (mainly HPV type 16) which disrupts the cell cycle through interaction between HPV proteins and the host cell. 2 Prophylactic vaccines against HPV have been developed to prevent HPV infection (and by extension, cervical cancer), achieving the best results if administered prior to the commencement of sexual activity. 3 However, a large proportion of the global population is already infected, and many women will continue to become infected with cervical cancer-associated HPV strains until global vaccine coverage is achieved. 4, 5 Furthermore, the long-term efficacy of the new HPV vaccines can only be evaluated decades after implementing the existing prophylactic vaccination. 6 Importantly, prophylactic vaccines protect the host against viral infection but are not designed to kill tumor cells. These limitations have prompted research into the development of therapeutic vaccines that treat HPV-related cancer. 2, [7] [8] [9] [10] [11] Therapeutic vaccine candidates against HPV-related cancers were usually designed to elicit a cytotoxic T-cell response by targeting E7 oncoprotein. This protein is constitutively expressed in cancer cells and is required for the induction and maintenance of tumor growth. T-cells recognize tumorassociated antigen in the form of a defined short peptide sequence (T cell epitope), rapidly and specifically killing target cells that display the antigen. 12 This approach to treating cancer overcomes the many disadvantages of classical chemotherapy, and other therapies like siRNA, which is severely limited by the instability and poor delivery of siRNA molecules into the targeted cells. Therapeutic vaccines use the body's natural fighting system, and have minimal risk of side effects.
5
All reported peptide-based therapeutic HPV vaccine candidates required formulation with an adjuvant (immunostimulant) to produce the desired immune response. 2 Not only are there a limited number of adjuvants approved for human use, but many of these adjuvants are associated with toxicity and low efficacy. 13 Therefore, the discovery and development of novel adjuvants with potent immunomodulatory activities is of significant importance in the field of cancer immunotherapy. Specifically, the development of potent and well-defined adjuvants without adverse toxicity is crucial to the success of therapeutic vaccines.
14 Dendrimers are structurally well-defined, synthetic polymers that can be designed to mimic the size and physiochemical properties of biomolecules (e.g. proteins). 15 Their hyperbranched structure allows the attachment and presentation of antigen molecules at the periphery of the dendrimer, resulting in a highly multifunctional biomacromolecule. 15 It was demonstrated that a Multiple Antigenic Peptide (MAP) system with a poly-lysine core 16 was able to generate high antibody titers as a prophylactic vaccine, but only when co-administered with an adjuvant. Similarly, linear polymers with the peptide epitopes randomly conjugated along the polymer backbone also generated antibody responses when co-administered with the toxic complete Freund's adjuvant (CFA). 17 To overcome these disadvantages, welldefined polymer-based amphiphiles were proposed. Polyacrylate was selected as the most promising candidate because polyacrylic acid and its esters were easy to synthesize and had little or no toxicity. 18, 19 We recently reported the ability of polyacrylate amphiphilic dendrimers (decorated with B-cell epitopes on the dendrimer's periphery) to act as a selfadjuvanting prophylactic vaccine, and induced a protective (humoral) immunity. 20, 21 However, while there are a substantial number of self-adjuvanting systems and adjuvants that induce humoral immunity, the induction of cellular responses for therapeutic vaccination is more challenging. For example, aluminium salts, the only adjuvant that is widely used in 6 humans, is recognized to essentially only stimulate a humoral immunity. 22, 23 Thus, there is an urgent need for alternatives that are able to induce cellular immune responses.
In this work, we hypothesized that a star polymer-based delivery systems might have the adjuvanting potency to generate T-cell mediated immunity against cells that produce the E7 protein, thus could eradicate tumor cells. We designed and synthesized polymer-peptide conjugates with the well-known HPV-16 E7 protein epitope 8Q
(QAEPDRAHYNIVTFCCKCD; E7 [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] ) which contains a CTL epitope (CD8 + cytotoxic T lymphocytes), and T-helper cell (CD4 + ) and B-cell epitopes ( Figure 1 ). 9 This combination makes 8Q an ideal candidate to stimulate long-term vaccine efficacy to kill cancer cells. We designed a short series of modified epitopes ( Figure 1 ) to avoid uncontrolled aggregation of the cysteine-rich 8Q epitope. These epitopes were conjugated to the dendritic structure that resembled a 4-arm star-polymer P( t BA 37 -≡) 4 (S4) and self-assembled into particles under aqueous conditions. All conjugates produced microparticles when formulated in phosphate buffer saline (PBS). A conjugate that contained the 8Q min epitope was able to reduce tumor growth and eradicate E7-expressing TC-1 tumors in mice after a single immunization, without help from any external adjuvant. Multiplicate measurements were performed at 25 °C with scattering angle of 173° using disposable cuvettes and the number-average hydrodynamic particle diameter are reported. 
Synthesis of Azidoacetic Acid (N 3 CH 2 CO 2 H).
Azidoacetic acid was synthesized using a similar method to published procedure. 25 Sodium azide (6.0 g, 92.3 mmol, 3.0 equiv.) was dissolved in H 2 O (10 mL) and bromoacetic acid (4.3 g, 30.8 mmol, 1.0 equiv.) was added.
The reaction was stirred continuously in an ice bath for 24 h and subsequently acidified with 32% HCl (10 mL). The product was then extracted with Et 2 O (4 x 50 mL), dried over anhydrous MgSO 4 and the solvent was evaporated under vacuum. The final product was obtained as a colorless oil (2.95 g, 95%) after prolonged evaporation under vacuum to was synthesized by manual stepwise SPPS on rink amide MBHA resin (substitution ratio: 4 (1.9 mg, 0.10 µmmol, 1.0 equiv.) were dissolved in DMF (1 mL).
The reaction was terminated after 12 h. The resulting particles were self-assembled into to yield diameters of around 150 nm and 700 nm as observed by dynamic light scattering. 4 (1.9 mg, 0.10 µmmol, 1.0 equiv.) were dissolved in DMF (1 mL).
Synthesis of Vaccine
The reaction was terminated after 12 h. The resulting particles were self-assembled into particles with a 26 nm diameter as observed by dynamic light scattering.
Mice and cell lines. Female C57BL/6 (6-8 weeks old) mice were used in this study and Statistical Analysis. All data were analyzed using GraphPad Prism 5 software. Kaplan-Meier survival curves for tumor treatment experiments were applied. Differences in survival treatments were determined using the log-rank (Mantel-Cox) test, with p < 0.05 considered statistically significant.
RESULTS AND DISCUSSION
Synthesis and characterization of the polymer-peptide conjugates. Coppercatalyzed alkyne-azide 1,3-dipolar cycloaddition (CuAAC) "click" reaction 34 was used to synthesize vaccine candidates against HPV-associated cancers. These candidates possessed a hydrophobic polymeric core and multiple copies of a peptide epitope derived from the HPV-16 E7 oncoprotein. The 8Q epitope and its new analogues were applied as antigens, while the polyacrylate 4-arm star-polymer served as a delivery platform. All the peptides contained CTL, T-helper, and B-cell epitopes.
First, the alkyne-functionalized 4-arm poly(t-butyl acrylate) star (S4) was synthesized by atom-transfer radical polymerization (ATRP) and end-group functionalization with a very narrow molecular-weight distribution (polydispersity index of less than 1.06). 8Q epitope and its azide (N 3 CH 2 CO-QAEPDRAHYNIVTFCCKCD-NH 2 ) were synthesized using with DBU for the removal of Fmoc groups after coupling isoleucine, valine and threonine.
To examine the 'click' reaction, simple model compounds were designed, in which an alkyne (1) and a dipeptide azide possessing single thiol functionality (2) were coupled using copper-wires as the catalyst (Scheme 1). 21, [39] [40] [41] Analysis of the reaction showed that instead of the desired 'click' product 3, a disulfide bond-mediated dimer of 2 was exclusively produced.
Subsequently, this dimer reacted with alkyne 1 producing disulfide bond-mediated dimer of compound 3 ( Figure S2 ). Thus, formation of the single product could not be expected during conjugation of S4 core with 8Q peptide which possessed multiple thiol groups. In an effort to eliminate disulfide bond formation, we investigated alternative CuAAC 'click' reaction conditions by changing the copper source (copper wire, copper sulfate, copper iodide), reducing agents (ascorbic acid, tris(2-carboxyethyl)phosphine), solvents (DMF, acetonitrile/water/trifluoroacetic acid, 90/10/0.1) and temperature (50 °C, RT). Regardless of the experimental conditions, we were unable to obtain compound 3 ( Figure S3 ). Scheme 1. The CuAAC reaction was examined using the model compounds 1 and 2.
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( Figure S4 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 19 synthesis of the 8Q epitope. Despite the use of DBU for removal of the protective Fmoc group, 8Q Ser azide was obtained in relatively poor yield after tedious purification. The isopeptide method developed by Kiso and coworkers was previously applied to the synthesis of peptides containing a "difficult" sequence. [42] [43] [44] [45] Thus, isodipeptide unit (Boc-Thr(FmocVal)-OH) was synthesized in a similar manner to the reported procedure, [26] [27] [28] and applied to the synthesis of 8Q Ser azide (Scheme S1) to avoid aggregation of the peptide during SPPS. 44 The final compound was obtained after O-N acyl migration of the O-acyl isoform, with significantly improved purity and yield (Figure 2 ). Both epitopes (8Q Ser and 8Q Lys ) were coupled to S4 to produce the desired conjugates (Scheme 2). The coupling for S4-8Q Ser and S4-8Q Lys was calculated to be (on average) 3.0 (75%) and 3.0 (74%) epitopes per S4, respectively. Conjugation of peptides to the polymer followed by self-assembly and dialysis was repeated several times, producing virtually identical products.
Both compounds (S4-8Q Ser and S4-8Q Lys ) were self-assembled in DMF/water and dialyzed against water. DLS analysis indicated that S4-8Q Ser formed large nanoparticles (~ 530 nm; Figure S4 ). In contrast, the size distribution of S4-8Q Lys particles was narrow, and smaller nanoparticles (26 nm) were detected ( Figure S4 ). To prepare samples for in vivo experiments, S4-8Q min , S4-8Q Ser and S4-8Q Lys were formulated in PBS. All of the conjugates formed a milky suspension upon addition of the buffer (pH = 7.4). Confocal images were used to visualize microparticles and their aggregates ( Figure S5 ). We were unable to quantitatively determine particles size distribution using DLS, TEM, and analytical ultracentrifugation. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   20 of S4 and 8Q, S4 alone and PBS). Mice were monitored every two days for evidence of tumor growth by palpation and calipers for 60 days. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 [48] [49] [50] In addition, size can play important role in immune responses, while some groups reported that immune responses were significantly stronger for small nanoparticles (less than 100 nm), 51, 52 others claimed that microparticles are required for strong activation of the immune system. 53, 54 Small nanoparticles can easily migrate to lymphatic nodes for antigen presentation, whereas large particles are transported to lymphatic nodes by dendritic cells and the immunity induced by large particles is often related to the depot effect. 55 Interestingly, T-cell activation is often facilitated by the extended presence of antigen through depot-forming adjuvants. 54 The three conjugates form microparticles and have the tendency to aggregate further. This observation may suggest that the differences in the conjugates antitumor activity are not related to particle size.
Polymer-peptide conjugate S4-8Q min demonstrated self-adjuvanting activity because it induced a therapeutic effect against tumor cells without help of any external adjuvant. This delivery system overcomes the poor immunogenicity of peptide-based vaccines and the common toxic side effects associated with external adjuvants. Self-adjuvanting properties of the polymer-based delivery system can be explained by particle-attributed activation of the immune system. 16, 56, 57 Particulate vaccines potentially cross-present the antigen, and antigen cross-presentation is especially important to induce the priming of the CD8 + T-cell immune responses that naturally play a crucial role for therapeutic vaccines against cancer. This delivery system also exploits the depot effect (i.e. retaining the antigen at the injection site), 23 thus increasing the duration of vaccine exposure to the immune cells. In addition, as particles are covered by multiple copies of the same peptide antigen, they should possess the advantages of a MAP system. Furthermore, formulation of antigens into particles provides some protection against enzymatic degradation, which is important for highly susceptible peptide antigens. Noticeably, in contrast to many previously reported peptide-based vaccine candidates, 33, 46, 47, 58 S4-8Q min demonstrated a therapeutic effect after a single immunization.
Conclusion
In conclusion, we established a synthetic pathway to produce polymer-peptide conjugates as macromolecular vaccine candidates against HPV-related cancers. The synthesis of peptide epitopes was greatly improved by the change of standard SPPS procedure and application of the isopeptide method. Modification of the immunogenic epitope allowed the elimination of undesirable disulfide bond-based aggregation/polymerization of the polymerpeptide conjugates.
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